A Phase 4 interventional study of 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen and 150 mcg Duramorph + multi-modal pain regimen in Elective Cesarean Section and Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 18 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-18.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare total opioid consumption by subjects in different treatment groups.
Another purpose of this study is to assess how well EXPAREL works, collect any safety data and assess your satisfaction using EXPAREL.
This is a Phase-4, multicenter, randomized, active-controlled study in approximately 182 adult women undergoing elective C-section. All subjects will remain in the hospital for up to 72 hours post surgery.
Subjects will be screened within 30 days prior to surgery. During the screening visit, subjects will be assessed for any past or present medical conditions that in the opinion of the investigator would preclude them from study participation.
After the Informed Consent Form (ICF) is signed, a medical history, surgical history, physical examination, 12-lead electrocardiogram (ECG), vital sign measurements, alcohol breath test and urine drug screen, and clinical laboratory tests (hematology and chemistry) will be performed.
On Day 1, prior to the C-section, eligible subjects will be randomized in a 1:1:1 ratio into one of the three treatment groups listed below:
Rescue Medication will be provided, as needed, for all subjects.
Subjects will remain in the hospital for up to 72 hours after surgery.
Total opioid burden and Pain intensity scores using a 10 cm Visual Analog Scale (VAS) will be collected.
Daily pain intensity score (VAS) and all pain medications will be collected through Day 14.
A phone call will be made to each subject on Day 14 and Day 30.
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
Drug: 150 mcg Duramorph + multi-modal pain regimen
50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen
EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
Drug: Exparel TAP + multi-modal pain regimen
Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
EXPAREL administered via TAP infiltration + multi-modal pain regimen.
Total Postsurgical Opioid Consumption Through 72 Hours
To Compare total opioid consumption through 72 hours following EXPAREL infiltration into the Transversus abdominus plane (TAP) with SOC in subjects undergoing an elective C-section
Time frame: Through 72 hours post-surgery
Percentage of Opioid-free Subjects
Percentage of opioid-free subjects. LS Means probability from the logistic regression with treatment, site, age, and height as explanatory variables.
Time frame: through 72 hours or hospital discharge, whichever came first
Severity of Itching (Numeric Rating Scale Score)
Severity of itching (Numeric Rating Scale score from 0(being none)-10(being the worst))
Time frame: through 72 hours after surgery
Opioid Related Symptom Distress Scale Score (ORSDS)
The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 10 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 10 symptom-specific scores. Each question will receive a score from 0-4 the composite score for each subject is the average of all scores. A higher score indicates a worse outcome.
Time frame: through 72 hours after surgery
| Milestone | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| Started | 56 | 56 | 55 |
| Completed | 53 | 47 | 51 |
| Not completed | 3 | 9 | 4 |
| Withdrew: Protocol violation | 3 | 5 | 3 |
| Withdrew: Delivered early | 0 | 1 | 0 |
| Withdrew: Not suitable to proceed | 0 | 1 | 0 |
| Withdrew: Difficult surgery | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
To Compare total opioid consumption through 72 hours following EXPAREL infiltration into the Transversus abdominus plane (TAP) with SOC in subjects undergoing an elective C-section
| OMED mg | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| Total Postsurgical Opioid Consumption Through 72 Hours | 69.3 ± 1.15 | 36.1 ± 1.16 | 22.1 ± 1.16 |
Percentage of opioid-free subjects. LS Means probability from the logistic regression with treatment, site, age, and height as explanatory variables.
| percentage of participants, opioid free | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| Percentage of Opioid-free Subjects | 22.4 | 28.8 | 30 |
Severity of itching (Numeric Rating Scale score from 0(being none)-10(being the worst))
| score on a scale | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| Severity of Itching (Numeric Rating Scale Score) | 1.48 ± 0.161 | 0.94 ± 0.176 | 0.61 ± 0.167 |
The Opioid-Related Symptom Distress Scale (ORSDS) is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 10 symptoms. The symptom-specific ORSDS is the average of the 3 symptom distress dimensions. The composite ORSDS is the average of 10 symptom-specific scores. Each question will receive a score from 0-4 the composite score for each subject is the average of all scores. A higher score indicates a worse outcome.
| score on a scale | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| Opioid Related Symptom Distress Scale Score (ORSDS) | 0.33 ± 0.055 | 0.23 ± 0.053 | 0.35 ± 0.051 |
Collected over Adverse events and serious adverse events (SAEs) were recorded from the time the ICF was signed through Day 14.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (Standard of Care Group) | 0/53 (0%) | 2/53 (3.8%) | 43/53 (81.1%) |
| Group 2 (Duramorph + EXPAREL TAP) | 0/48 (0%) | 2/48 (4.2%) | 41/48 (85.4%) |
| Group 3 (EXPAREL TAP) | 0/52 (0%) | 2/52 (3.8%) | 30/52 (57.7%) |
| Event | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/53 | 1/48 | 0/52 |
| ConstipationGastrointestinal disorders | 0/53 | 1/48 | 0/52 |
| Postpartum hemorrhageInjury, poisoning and procedural complications | 0/53 | 0/48 | 1/52 |
| Abdominal wall hematomaInjury, poisoning and procedural complications | 0/53 | 0/48 | 1/52 |
| Incision Site PainInjury, poisoning and procedural complications | 1/53 | 0/48 | 0/52 |
| Pre-eclampsiaPregnancy, puerperium and perinatal conditions | 1/53 | 0/48 | 0/52 |
| Event | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 25/53 | 28/48 | 16/52 |
| NauseaGastrointestinal disorders | 16/53 | 9/48 | 2/52 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 9/53 | 6/48 | 4/52 |
| ConstipationGastrointestinal disorders | 6/53 | 2/48 | 7/52 |
| Abdominal distentionGastrointestinal disorders | 6/53 | 6/48 | 2/52 |
| Incision site pruritusInjury, poisoning and procedural complications | 1/53 | 4/48 | 2/52 |
| DizzinessNervous system disorders | 2/53 | 4/48 | 1/52 |
| RashSkin and subcutaneous tissue disorders | 3/53 | 4/48 | 0/52 |
| FlatulenceGastrointestinal disorders | 2/53 | 0/48 | 4/52 |
| VomitingGastrointestinal disorders | 4/53 | 2/48 | 0/52 |
| Age, Continuous(years) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| Mean | 33.2 ± 4.67 | 34.1 ± 4.93 | 32.7 ± 5.03 | 33.3 ± 4.88 |
| Sex: Female, Male(Participants) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| Female | 53 | 48 | 52 | 153 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 7 | 18 |
| Not Hispanic or Latino | 46 | 43 | 45 | 134 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 3 | 5 | 8 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 7 | 15 |
| White | 41 | 36 | 34 | 111 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 3 | 3 | 3 | 9 |
| Region of Enrollment(participants) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| United States | 53 | 48 | 52 | 153 |
| American Society of Anesthesiologists (ASA) Physical Status Classification(Participants) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| ASA I | 2 | 0 | 3 | 5 |
| ASA II | 47 | 45 | 39 | 131 |
| ASA III | 4 | 3 | 10 | 17 |
| Body Mass Index (pre-pregnancy)(kg/m^2) | Group 1 (Standard of Care Group) | Group 2 (Duramorph + EXPAREL TAP) | Group 3 (EXPAREL TAP) | Total |
|---|---|---|---|---|
| Mean | 31.69 ± 5.091 | 31.08 ± 5.181 | 32.23 ± 6.179 | 31.68 ± 5.490 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Jan 2020, 10 months.
Results were first posted in Jul 2022, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Agnosia